Pharma IQ Members

Assay Development

Assay Development is a procedure in molecular biology for testing or measuring the activity of a drug or biochemical in an organism or organic sample. A quantitative assay may also measure the amount of a substance in a sample. Bioassays and immunoassays are among the many varieties of specialized biochemical assays. Other assays measure processes such as enzyme activity, antigen capture, stem cell activity, and competitive protein binding.

14 results
of 2
Gerald Clarke

Why are NASA using human stem cells to study the chicken pox virus? How could this help astronauts in space?  How is the Mars Rover mission helping?  And why are the Russians so interested?  Find out with Thomas J. Goodwin, Manager, Disease...

Contributor: Gerald Clarke
Mon, 11/04/2013
The pre-clinical phase of drug discovery  involves many years of research being conducted by multi-disciplinary teams. These teams will generate significant amounts of data which are processed using standard as well as specialist software.  ...
Contributor: Sheraz Gul
Wed, 08/29/2012
hESC derived Cytiva™ Cardiomyocytes for Drug Safety Testing

This video presentation demonstrates how hESC derived cardiomyocytes can be a powerful approach to assessing cardiac drug liabilities. Nick Thomas describes how hESC derived Cytiva Cardiomyocytes: • are a valid model of cardiomyocytes from the...

Thu, 04/19/2012
Andrea Charles

In this podcast Mark Hembarsky, Vice President and Site Leader of the Aptuit Medicines Research Centre in Verona, Italy, and his colleagues Mauro Corsi, Head of Assay Development and In Vitro Profiling Preclinical Technologies, Sergio Raimondo,...

Contributor: Andrea Charles
Wed, 09/07/2011
Andrea Charles

The lengthy clinical development process of drug development for life threatening diseases is not an optimal development strategy for oncology therapeutic area. Adaptive designs have become popular tools in oncology research, helping to achieve...

Contributor: Andrea Charles
Mon, 06/06/2011
Pharma IQ News

This May, Joao Pedras-Vasconcelos, Visiting Associate, Therapeutic Proteins CBER from FDA will meet with European industry experts at Pharma IQ's Immunogenicity event to discuss FDA directives on Immunogenicity introduced in 2008.  Over the last...

Contributor: Pharma IQ News
Mon, 04/04/2011
Andrea Charles

As part of the Pharma Leaders Today Series Dr. Keith Horspool, Vice President, Pharmaceutical Development US, Boehringer Ingelheim, speaks to Andrea Charles from Pharma IQ, about why changes are needed to current preformulation and formulation...

Contributor: Andrea Charles
Mon, 03/14/2011
Assay Development and Immunogenicity Testing

Immunogenicity is becoming an integral feature within drug development activities. Testing immunogenicity, however, presents those within the pharmaceutical industry with a host of challenges; ones which must be overcome as developers look to...

Contributor: Pharma IQ
Thu, 02/24/2011
The Process of Drug Development: Time to Market

The term Drug Development covers a wide range of activities, from clinical trials to the creation of new compounds, all of which help drive a particular product to market. In its entirety, the process can take more than a decade, and cost...

Contributor: Pharma IQ
Tue, 11/09/2010
Pharma IQ

Dr. Timothy Robison, Pharmacology/Toxicology Reviewer at the US Food and Drug Administration/CDER, joins Helen Winsor from Pharma IQ, to share the latest insights into achieving successful characterisation of genotoxic impurities and accurate...

Contributor: Pharma IQ
Tue, 09/21/2010
14 results
of 2